Hematologic Neoplasm Clinical Trials

1 recruiting

Hematologic Neoplasm Trials at a Glance

20 actively recruiting trials for hematologic neoplasm are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Bethesda, New York, and Boston. Lead sponsors running hematologic neoplasm studies include National Cancer Institute (NCI), Cogent Biosciences, Inc., and Azienda USL Reggio Emilia - IRCCS.

Browse hematologic neoplasm trials by phase

Treatments under study

About Hematologic Neoplasm Clinical Trials

Looking for clinical trials for Hematologic Neoplasm? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematologic Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematologic Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NeoplasmsHealthy VolunteersHematologic Neoplasms
National Heart, Lung, and Blood Institute (NHLBI)6,000 enrolled1 locationNCT00071045
Recruiting
Phase 1Phase 2

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms
National Cancer Institute (NCI)430 enrolled1 locationNCT05327023
Recruiting
Phase 1Phase 2

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Hematologic Neoplasms
National Cancer Institute (NCI)320 enrolled2 locationsNCT04959175
Recruiting
Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 2

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more
Cogent Biosciences, Inc.140 enrolled42 locationsNCT04996875
Recruiting
Not Applicable

Cognitive Training Intervention and Attitudes Towards Genetics

Cognitive ImpairmentHematologic NeoplasmsHematopoietic Cell Transplant
University of Alabama at Birmingham60 enrolled1 locationNCT03094026
Recruiting
Not Applicable

LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)

Hematologic NeoplasmsOncologic Disorders
Technical University of Munich150 enrolled1 locationNCT07519811
Recruiting
Not Applicable

Mind-body Medicine for Patients With Malignant Hematological Diseases

Hematologic Neoplasms
Universität Duisburg-Essen94 enrolled1 locationNCT03735992
Recruiting

UWCCC Molecular Tumor Board Registry

Solid NeoplasmHematologic Neoplasms
University of Wisconsin, Madison10,000 enrolled1 locationNCT03023202
Recruiting
Phase 1

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm
H. Lee Moffitt Cancer Center and Research Institute34 enrolled7 locationsNCT06327685
Recruiting
Phase 3

Influenza Vaccination Strategy for Patients With Hematologic Malignancy

Hematologic NeoplasmsInfluenzaImmunogenicity
Asan Medical Center60 enrolled1 locationNCT07485855
Recruiting
Not Applicable

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Hematopoietic and Lymphatic System NeoplasmHematologic NeoplasmsMyeloid Malignancy+10 more
Mayo Clinic2,000 enrolled3 locationsNCT02958462
Recruiting
Not Applicable

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

Hematologic Neoplasms
Hemanext24 enrolled1 locationNCT06685848
Recruiting
Phase 3

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)

Hematologic Neoplasms
Ottawa Hospital Research Institute662 enrolled12 locationsNCT04448184
Recruiting

Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers

Multiple Myeloma (MM)Hematologic Neoplasm
Azienda USL Reggio Emilia - IRCCS190 enrolled1 locationNCT07014865
Recruiting
Not Applicable

Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation

Hematologic Neoplasms
National Cancer Institute, Slovakia100 enrolled1 locationNCT04691284
Recruiting

Prospective Validation of the OHI Index

Hematologic MalignancyHematologic NeoplasmsHLH+2 more
Meir Medical Center300 enrolled2 locationsNCT05882175
Recruiting
Not Applicable

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Hematologic NeoplasmsNeutropenia
Instituto Nacional de Cancerologia de Mexico226 enrolled1 locationNCT06422533
Recruiting

Bleeding In Thrombocytopenia Explained

Hematologic NeoplasmsBleedingHemorrhage
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research1,000 enrolled1 locationNCT03505086
Recruiting

The feasibility of Enteral Nutrition (EN) support in Allogeneic Haematopoietic Stem Cell Transplantation.

Hematologic Neoplasms
Shannon Petrovic10 enrolled1 locationACTRN12619000942156